NDA 022363 · Kowa CO
Livalo
Pitavastatin Calcium · Oral
NovelLast checked: Nov 20, 2026Latest source record: Mar 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Aug 3, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
112
25 Phase 3, 12 recruiting
FAERS reports
8,612
6,027 serious, 706 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 31, 2026.
LIVALO is indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). LIVALO is a HMG-CoA reductase inhibitor (statin) indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: ( 1 ) Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
Mechanism: Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a rate-limiting step in the biosynthetic pathway for cholesterol. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very low density lipoproteins.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 16, 2019 Supplement 15 · Efficacy · priority review LetterLabelPediatric Medical Review
- Nov 18, 2016 Supplement 11 · Efficacy LetterLabel
- Aug 3, 2009 Original approval · Type 1 - New Molecular Entity NovelLabelReviewPediatric Written Request
3 products under this application
- LIVALO · PITAVASTATIN CALCIUM EQ 2MG BASE · TABLET, ORAL · Prescription · TE AB
- LIVALO · PITAVASTATIN CALCIUM EQ 4MG BASE · TABLET, ORAL · Prescription · TE AB
- LIVALO · PITAVASTATIN CALCIUM EQ 1MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pitavastatin" as an intervention, any sponsor and status, largest first.
- Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)Pivotal-lookingCompleted
Juntendo UniversityAcademic, hospital or other
NCT01042730 · 13,054 participants · Start Feb 2010 · Primary completion Jun 2016
Drug: Pitavastatin 1 mg daily or 4 mg daily · For: Coronary Artery Disease
Sites: Kyoto, Japan; Tokyo, Japan
Fudan UniversityAcademic, hospital or other
NCT03418974 · 10,000 participants · Start Nov 1, 2017 · Primary completion Dec 31, 2021
Drug: Pitavastatin; Atorvastatin and 1 more · For: Dyslipidemias
Sites: Beijing, China; Shanghai, China
- Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected AdultsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT02344290 · 7,769 participants · Start Mar 26, 2015 · Primary completion Aug 21, 2023
Drug: Pitavastatin; Placebo · For: HIV; Cardiovascular Diseases
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 137 sites in all
- GUIDE-CAC: Statin-Ezetimibe Without Aspirin vs. Statin Monotherapy With Aspirin in High Coronary CalcificationPivotal-lookingRecruiting
Asan Medical CenterAcademic, hospital or other
NCT06722521 · 7,435 participants (planned) · Start Jul 9, 2025 · Primary completion Jun 30, 2032
Drug: Pitavastatin 4mg and ezetimibe 10mg, taken once daily; Pitavastatin 2 mg with aspirin 100 mg, taken once daily. · For: Primary Prevention; Vascular Calcification
Sites: Seoul, South Korea
- Livalozet Versus High-intensity Statin in Older Patients With Coronary Artery Disease Undergoing Percutaneous Coronary InterventionPivotal-lookingNot yet recruiting
Samsung Medical CenterAcademic, hospital or other
NCT07626840 · 5,000 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 1, 2028
Drug: Pitavastatin/ezetimibe; Atorvastatin or Rosuvastatin · For: Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese PopulationPivotal-lookingRecruiting
China National Center for Cardiovascular DiseasesGovernment (non-federal)
NCT06096909 · 3,684 participants (planned) · Start Nov 11, 2023 · Primary completion Mar 1, 2028
Drug: Tafolecimab; Cholesterol Absorption Inhibitor and 1 more · For: Acute Coronary Syndrome; Non ST Segment Elevation Acute Coronary Syndrome; Lipid Lowering, Vascular Inflammation
Sites: Beijing, China; Tangshan, China
- Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes MellitusPivotal-lookingRecruiting
Korea University Anam HospitalAcademic, hospital or other
NCT06767774 · 2,000 participants (planned) · Start Apr 25, 2025 · Primary completion Aug 31, 2029
Drug: Combination therapy; High intensity statin monotherapy · For: ASCVD; Diabetes; Statin
Sites: Seoul, South Korea
- Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVDPivotal-lookingRecruiting
Yonsei UniversityAcademic, hospital or other
NCT07524101 · 1,952 participants (planned) · Start May 28, 2026 · Primary completion Jan 22, 2031
Drug: Moderate-intensity statin and ezetimibe combination therapy; High-intensity statin monotherapy · For: Renal Insufficiency; Atherosclerosis; Dyslipidemia and 2 more
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myalgia480
- diarrhoea393
- nausea374
- fatigue359
- anaemia300
- headache298
- dizziness297
- arthralgia295
- rash287
- off label use265
- dyspnoea260
- drug ineffective254
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 9 |
| 2006 | 25 |
| 2007 | 38 |
| 2008 | 67 |
| 2009 | 78 |
| 2010 | 171 |
| 2011 | 274 |
| 2012 | 545 |
| 2013 | 375 |
| 2014 | 553 |
| 2015 | 660 |
| 2016 | 725 |
| 2017 | 707 |
| 2018 | 685 |
| 2019 | 656 |
| 2020 | 515 |
| 2021 | 417 |
| 2022 | 477 |
| 2023 | 419 |
| 2024 | 526 |
| 2025 | 383 |
| 2026 | 303 |
Recalls
2 FDA enforcement reports for this application.
Feb 24, 2025 · Class III · Completed
Presence of foreign tablets/capsules
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Livalo (Pitavastatin Calcium)
2024 spending
$90.6M
Beneficiaries
37,775
143,372 claims
Per beneficiary
$2,399
$10.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $189,564,416 |
| 2021 | $206,236,202 |
| 2022 | $206,857,254 |
| 2023 | $189,914,605 |
| 2024 | $90,623,325 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Statin therapy increases lipoprotein(a) levels.
Tsimikas S, Gordts PLSM, Nora C, et al. · Eur Heart J 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Interaction potential between clarithromycin and individual statins-A systematic review.
Hougaard Christensen MM, Bruun Haastrup M, Øhlenschlaeger T, et al. · Basic Clin Pharmacol Toxicol 2020 · Comparative Study, Systematic Review
- Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.
Grinspoon SK, Fitch KV, Zanni MV, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.
Zhang X, Xing L, Jia X, et al. · Cardiovasc Ther 2020 · Network Meta-Analysis, Systematic Review
- Pravastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Tasnim S, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Meta-Analysis
- Pitavastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Wright JM · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Kowa CO
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.